Literature DB >> 24462138

Association of interleukin 8 with myocardial infarction: results from the Stockholm Heart Epidemiology Program.

Ilais Moreno Velásquez1, Paolo Frumento2, Katarina Johansson3, Anita Berglund4, Ulf de Faire5, Karin Leander4, Bruna Gigante6.   

Abstract

BACKGROUND: Interleukin 8 (IL8) has been contradictorily associated with the risk of myocardial infarction (MI). AIM: To investigate the association of IL8 serum levels with the risk of MI and the association of the IL8 (IL8) and IL8 receptors (CXCR1 and CXCR2) genetic variants with IL8 levels and MI risk in a large case control study, the Stockholm Heart Epidemiology Program. METHODS AND
RESULTS: IL8 levels (pg/mL) were divided into quartiles and the MI risk was calculated by logistic regression and expressed as odds ratio (OR) and 95% CI. Two IL8 SNPs (rs4073A/T, rs2227306C/T) and three SNPs tagging CXCR1 and CXCR2 (rs4674258C/T, rs1008563C/T, rs6723449T/C) were analyzed for association with IL8 levels and with MI risk. Multivariate adjusted ORs for MI risk by IL8 levels in the highest quartiles indicated reduced point estimates in both women (OR 0.37; 95% CI 0.2-0.8) and men when compared to the lowest quartile. In female cases, IL8 levels decreased progressively in the six months after MI (p=0.03). IL8, CXCR1 and CXCR2 genetic variants were not associated with IL8 levels. In men, the T allele at the IL8 SNP rs4073 was associated with a slight increase in the MI risk under an additive and a recessive model of inheritance.
CONCLUSIONS: IL8 serum levels were associated with a reduced occurrence of MI among women, whereas IL8 was associated with a slightly increased risk among men, possibly through different mechanisms. These data suggest that the biological effects of IL8 on MI risk may vary over time and warrant further cohort studies with repetitive IL8 measurements.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Biomarker; Genetic variants; Interleukin 8; Myocardial infarction

Mesh:

Substances:

Year:  2014        PMID: 24462138     DOI: 10.1016/j.ijcard.2013.12.170

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

Review 1.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

2.  IL-8 up-regulates proliferative angiogenesis in ischemic myocardium in rabbits through phosphorylation of Akt/GSK-3β(ser9) dependent pathways.

Authors:  Qiying Xie; Zelin Sun; Meifang Chen; Qiaoqing Zhong; Tianlun Yang; Jun Yi
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Serum CD121a (Interleukin 1 Receptor, Type I): A Potential Novel Inflammatory Marker for Coronary Heart Disease.

Authors:  Zhengxia Liu; Mengyao Zhang; Jin Wu; Ping Zhou; Ying Liu; Yucheng Wu; Yujiao Yang; Xiang Lu
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

4.  Association between higher expression of interleukin-8 (IL-8) and haplotype -353A/-251A/+678T of IL-8 gene with preeclampsia: A case-control study.

Authors:  Lei Sun; Dongwei Mao; Yan Cai; Wenhua Tan; Yanlan Hao; Lin Li; Wei Liu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

5.  Exposure to Traffic-Related Air Pollution and Serum Inflammatory Cytokines in Children.

Authors:  Olena Gruzieva; Simon Kebede Merid; Anna Gref; Ashwini Gajulapuri; Nathanaël Lemonnier; Stéphane Ballereau; Bruna Gigante; Juha Kere; Charles Auffray; Erik Melén; Göran Pershagen
Journal:  Environ Health Perspect       Date:  2017-06-16       Impact factor: 9.031

6.  Strong association between the interleukin-8-251A/T polymorphism and coronary artery disease risk.

Authors:  Ying Wu; Wei Wang; Xiao-Yan Li; Ling-Ling Qian; Shi-Peng Dang; Xu Tang; Heng-Jian Chen; Ru-Xing Wang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

7.  Serum IL8 is not associated with cardiovascular events but with all-cause mortality.

Authors:  Ilais Moreno Velásquez; Ashwini Gajulapuri; Karin Leander; Anita Berglund; Ulf de Faire; Bruna Gigante
Journal:  BMC Cardiovasc Disord       Date:  2019-02-04       Impact factor: 2.298

8.  Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.

Authors:  Laura M Tsujikawa; Li Fu; Shovon Das; Christopher Halliday; Brooke D Rakai; Stephanie C Stotz; Christopher D Sarsons; Dean Gilham; Emily Daze; Sylwia Wasiak; Deborah Studer; Kristina D Rinker; Michael Sweeney; Jan O Johansson; Norman C W Wong; Ewelina Kulikowski
Journal:  Clin Epigenetics       Date:  2019-07-12       Impact factor: 6.551

9.  An IL-6-IL-8 score derived from principal component analysis is predictive of adverse outcome in acute myocardial infarction.

Authors:  Gisela A Kristono; Ana S Holley; Kathryn E Hally; Morgane M Brunton-O'Sullivan; Bijia Shi; Scott A Harding; Peter D Larsen
Journal:  Cytokine X       Date:  2020-10-08

10.  Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.

Authors:  Sylwia Wasiak; Dean Gilham; Laura M Tsujikawa; Christopher Halliday; Karen Norek; Reena G Patel; Kevin G McLure; Peter R Young; Allan Gordon; Ewelina Kulikowski; Jan Johansson; Michael Sweeney; Norman C Wong
Journal:  Data Brief       Date:  2016-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.